Press Releases

BOC Sciences Launches A New Liposome Technology Platform

Rho Experts Offer Free Webinar on Mitigating COVID-19 through Hybrid Decentralized Clinical Trials

Rho, a full-service contract research organization (CRO) that helps pharmaceutical and biotechnology companies bring their products to market through high-quality clinical research services, will share best practices and solutions to help sponsors get the most out of their hybrid, virtual and synthetic clinical trials in an upcoming webinar, “Mitigating COVID-19 through a hybrid decentralized clinical trials approach.” The webinar will take place on Wednesday, October 7, from 1-2 p.m. EST.

AARDEX Group partners with BIOCORP to extend digital solutions for precision medication adherence

Belgium-based AARDEX Group, the world leader in medication adherence solutions, today announced a strategic partnership with BIOCORP, a French company specialized in the design, development and manufacture of innovative medical devices. The alliance will further extend the comprehensive portfolio of smart solutions and connected devices available to effectively measure and manage medication adherence for patients and healthcare providers.

Panthera Biopartners concludes Series A financing with Gresham House Ventures as major investor

Panthera Biopartners (Panthera) has completed a Series A funding round with Gresham House Ventures as a major investor. The capital raised will enable Panthera to further build out its network of clinical trial sites across the UK and overseas and increase its team of clinical trial experts in serving both pharma and patients.

PRC Clinical Galvanizes Brand

PRC Clinical has galvanized its brand and website to reflect its increasingly specialized, high-touch approach to early phase clinical research. The vision of PRC showcases its commitment to providing customized CRO service for pharmaceutical, biotech and medical device sponsors.

TrialScope Adds Eisai to Its Community of Study Sponsors

TrialScope, the global leader in clinical trial disclosure and transparency management technology, has added Eisai to its growing customer roster.

New Zealand’s Ubiquitome signs NIH RADx contract

Ubiquitome, the only company outside the US, has received NIH RADx funds to develop its open RT-PCR the Liberty16 to test for COVID-19 in US hospitals and mobile labs

Indica Labs announces launch of enterprise-wide, cloud-based digital pathology deployment at NCI

Indica Labs announced today the launch of an enterprise-wide, cloud-based deployment of the HALO®, HALO AI, HALO Link and HALO AP software within the National Cancer Institute (NCI) – which I thought would be of interest to you and your readers. The existing on-premise HALO licenses at the NCI are siloed and only accessible to specific research groups. The new deployment has been designed to expand accessibility to hundreds of users within the NCI, managing millions of digital images and facilitating the analysis of thousands of images daily. Taking a cloud-based approach, the deployment also simplifies data sharing and enables real-time collaboration between the NCI and both internal and external researchers in ways that were not previously possible.

Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda®, in the Company’s Phase 1 NOXCOVID-1 study.

Alfa Chemistry Materials Offers Wide Options of Resins for Decoration or Manufacture of Plastics

AI & Medicine’s Drug Research and Development Platform Assists Biomarker Discovery

CD Genomics Optimized NGS Oncology Panels for Cancer Related Research

Study Shows Proof of Concept of BioIVT HEPATOPAC Cultures with Targeted Assay to Evaluate Bioactivation Potential and Drug-induced Liver Injury (DILI) Risk

New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment 

Cytel ushers in new era of optimized clinical trial design with launch of Solara™

Cytel is set to revolutionize clinical trial design planning with the launch of SolaraTM, a collaborative decision-support platform for greater development productivity and better business results. Overcoming a critical bottleneck in pharma & biotech The platform will fundamentally reimagine clinical trial design – a process renowned for its tight design timelines and the convoluted process of reaching stakeholder consensus on the most suitable trial design. The only platform of its kind The platform applies massive cloud computing power to rapidly explore an exponentially larger design space than is possible using traditional design methods. It is the only platform to integrate statistical and business considerations into the trial design process and includes intuitive visualization tools to optimize decision-making.

BioIVT Launches HEPATOMUNE Kit to Facilitate Liver Toxicity and Inflammation Studies for Drug Discovery and Disease Research

Applications for this model include assessing drug candidates’ hepatotoxicity, and studying inflammation-related diseases 

ATMPS advanced therapy blockchain platform has successful testing with NHS partners

New ‘blockchain ecosystem’ has potential to track, from vein-to-vein, advanced therapies

Alfa Chemistry Testing Lab Builds an Exclusive Regulatory Resource Section on Its Website

SB3000 partners with Evaxion biotech to provide rapid scale up for commercial production of corona virus vaccines with its continuous manufacturing technology

SB3000 partners with Evaxion biotech to provide rapid scale up for commercial production of corona virus vaccines with its continuous manufacturing technology.

Sakura Finetek Europe launches Tissue-Tek SmartConnect®, a new chapter in automation and the next step for laboratories in achieving future-proof pathology.

https://news.lifesciencenewswire.com/newsroom/sakura-finetek-europe-launches-tissue-tek-smartconnect

Ben-Gurion University Researcher Develops and Licenses New Clinical Trials Platform Based on Machine Learning

The new platform leverages machine learning to optimize a clinical trial’s chances of success, by analyzing patient population recruitment and dropout rate, as well as identifying and prioritizing monitored markers. It provides efficient pre-trial recommendations, in-trial interim analysis, and post-trial insights for next trial preparation, as well as potential salvage options in case of failure.